GI & Hepatology CRO Expertise
Omega Research brings deep, global experience across a broad spectrum of gastrointestinal and liver diseases – from common to complex and rare indications. Our in-house medical leadership and therapeutically aligned operational teams bring proven expertise that drives high-quality execution and accelerates timelines. We’ve supported successful trials and RWE studies across key GI and hepatology indications, including
- Inflammatory bowel disease (IBD), including ulcerative colitis and Crohn’s disease
- Esophageal and gastric disorders, including GERD, NERD, eosinophilic esophagitis, and gastroparesis
- Functional gastrointestinal disorders, including irritable bowel syndrome (IBS), functional constipation, and functional diarrhea
- Metabolic dysfunction-associated steatohepatitis (MASH) and metabolic dysfunction-associated steatotic liver disease (MASLD), including MASH-related cirrhosis
- Alcoholic hepatitis and rare liver diseases
- Hepatitis B & C and other viral liver diseases
Collaborative & Cross-Functional Teams to Execute Your GI & Hepatology Study
At Omega Research, collaboration is at the core of our success in GI and hepatology clinical research. Our integrated teams – spanning medical, regulatory, and operational experts – work seamlessly to provide strategic oversight and execution at every stage of development.
Our key capabilities include:
- Comprehensive Site Selection & Management: Leveraging our global network of specialized GI and hepatology sites
- Centralized Imaging & Histopathology Coordination: Expert management of endoscopy, histology, and radiology core labs
- Advanced Laboratory Support: Specialized handling of biomarkers and novel laboratory endpoints
- Patient Recruitment Strategies: Tailored approaches for challenging GI and liver disease populations
- Real-World Evidence Generation: Post-marketing studies and treatment pattern analysis